Rule 3.19A.3

# Appendix 3Z

## **Final Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Australian Clinical Labs Limited (ACL)
ABN	94 645 711 128

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Andrew Mark Rendle Dutton
Date of last notice	28 April 2022
Date that director ceased to be director	25 October 2024

#### Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

#### Number & class of securities

None

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
Snazfam Pty Limited (ACN 131 872 565) as trustee for the AMR Dutton Superannuation Fund. Andrew Mark Rendle Dutton is a director of Snazfam Pty Limited and is a beneficiary of the AMR Dutton Superannuation Fund.	81,897 ordinary shares

### Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

<sup>+</sup> See chapter 19 for defined terms.